ClinicalTrials.gg
RecruitingNCT05474989LYTAUpdated Oct 7, 2026

LSD Treatment for Persons With Alcohol Use Disorder

A Phase 2 interventional study of LSD and Active placebo in Alcohol Use Disorder (AUD), sponsored by Felix Mueller. Recruiting at 2 sites in Switzerland. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Felix Mueller · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
25 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Alcoholism with a site in Switzerland — 4 open to participants now, 4 under way, none of them phase 3. Alcoholism · Switzerland.

Planned enrollment
2nd of 10
128 · median 57
Started
2026
with 1 other
Phase 2
4 of 12
2 open now
Registered
7th of 12
by date
Lead sponsor
1 of 12
Felix Mueller

Among the 12 studies in Alcoholism with a site in Switzerland, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 2, and was the 7th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

4 of the 12 studies in Alcoholism with a site in Switzerland are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 25 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Alcoholism with a site in Switzerland, or all of them as a file.
02

Study summary

Lysergic acid diethylamide (LSD) was investigated in numerous clinical trials during the 1950s and 1960s. Specifically, the use of LSD in the treatment of AUD was investigated extensively. A pooled analysis of six historical clinical trials demonstrated that a single dose of LSD significantly reduced alcohol use at three and six months after LSD administration. However, these trials are limited by several factors, including the use of diagnostic standards that are no longer up to date, single, high-dose treatment regimes, missing biological assessment for alcohol use, and no consequent assessment of blinding.

This trial will assess the efficacy and safety of two moderate to high doses of LSD to decrease alcohol consumption in patients with AUD. The trial has a double-blind, active placebo-controlled, randomized, parallel design and will be conducted in specialized treatment centers for addictive disorders in Switzerland. The study will include 128 patients who have undergone detoxification. Participants will be allocated to one of the two intervention arms (1:1 allocation). Each arm comprises nine study visits (no drug administration) and two study days (involving LSD administration) within 30 weeks. Patients allocated to the control intervention (active placebo group) will receive 10 µg LSD on the first study day and either 10 or 20 µg LSD on the second study day. Patients allocated to the treatment intervention will receive 150 µg LSD on the first study day and either 150 µg or 250 µg LSD on the second study day. The dose will be retained or increased depending on the patient's individual response on the first study day. Participants in the control intervention will be offered to attend an open-label LSD session (150 µg) at week 31. The open-label phase will comprise three additional visits. This trial will further compare the effectiveness of LSD-assisted therapy in both group and individual therapeutic settings. To this end, participants in both drug conditions will be randomly assigned to group or individual settings.

The primary outcome is the mean of percent heavy drinking days after administration of two doses of LSD during the 12 weeks following the second administration. Secondary objectives: The second aim of this study is to explore long-term changes in the cortical thickness, white matter microstructure, resting state functional connectivity (rs-FC) and cerebral blood flow (CBF) of regions associated with addiction pathophysiology. Furthermore, we will assess alterations in depressive symptoms, anxiety, and persisting effects of LSD. We will also assess biological markers of alcohol use and several predictors for treatment-response (genetics, personality traits, blinding, expectancy, and quality of acute drug effects). Lastly, we will compare LSD treatment within a group setting with treatment within an individual setting.

Patients will be followed up six months after the second administration in the double-blind phase. At this time point, a predefined subset of the questionnaires used in the main study will be administered (TLFB, SIP-2R, OCDS, drinking goals, self-efficacy, BSCL, BDI, and BAI; see below).

During the open-label phase, patients will be assessed one month after administration. This assessment will include a subset of questionnaires (TLFB, OCDS, BSCL, BAI, BDI, CHIME, WHOQOL-BREF, drinking goals, self-efficacy, and WVQ; see below). In addition, the open-label phase will include assessments of acute drug effects, expectancy, and adverse events (see below).

03

Conditions studied

  • Alcohol Use Disorder (AUD)

Browse trials for

04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  • Age ≥ 25 years
  • Participants must meet the criteria for a moderate to severe alcohol use disorder and must intend to stop or decrease their drinking for at least the duration of the study
  • Participants must have underwent an alcohol detoxification within the 60 days prior to screening or, in cases where no detoxification is necessary, must have been abstinent for at least 14 days.
  • A minimum of 4 HDD within the last 30 days before detoxification or cessation of alcohol use (a HDD is defined as 5 or more standard drinks per day for a man and 4 drinks for a woman; a standard drink is defined as 12 g of alcohol)

Key exclusion criteria:

  • Significant alcohol withdrawal symptoms at screening
  • Participating or starting in any formal treatment for AUD from visit 1 until completion of the double-blind phase
  • Treatment with disulfiram during the study
  • Past or present diagnosis of a DSM-5 psychotic or bipolar disorder in subjects or first-degree relatives
  • Current suicidality or history of a serious suicide attempt
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Verum

    Subjects in the treatment arm will receive 150 μg LSD (first session) and 150 or 250 μg LSD (second session).

    Drug: LSD

  • Active comparator
    Active placebo

    Subjects in the control arm will receive 10 µg LSD at the first session and 10 or 20 µg LSD at the second session.

    Drug: Active placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percent heavy drinking days

    The primary outcome is the mean percentage of heavy drinking days after administration of two doses of LSD assessed with the alcohol timeline follow-back (TLFB) questionnaire compared between treatment groups

    Time frame: Period of three months after the second administration

Secondary outcomes

  1. Cortical thickness measured with MRI

    Changes in the cortical thickness of the ACC, PCC, and PFC

    Time frame: One month after the first administration, one month after second administration

  2. The volume of the striatum measured with MRI

    Changes in the volume of the striatum

    Time frame: One month after the first administration, one month after second administration

  3. White matter microstructure measured with MRI

    Changes in white matter microstructure in the cingulum bundle and the PFC-striatal connection pathway

    Time frame: One month after the first administration, one month after second administration

  4. Days to first heavy drinking day

    Days to first heavy drinking day after the first and second administration assessed with TLFB

    Time frame: One month after the first administration, one, two, and three months after the second administration

  5. Days to first drinking day

    Days to first drinking day assessed after the first and second administration assessed with TLFB

    Time frame: One month after the first administration, one, two, and three months after the second administration

  6. Percent days abstinent

    Percent days abstinent after the first and second administration assessed with TLFB

    Time frame: One month after the first administration, one, two, and three months after the second administration

  7. Drinks per drinking day

    Drinks per drinking day after the first and second administration assessed with TLFB

    Time frame: One month after the first administration, one, two, and three months after the second administration

  8. Percent heavy drinking days

    Percent heavy drinking days assessed with TLFB

    Time frame: One month after the first administration

  9. Adverse consequences of alcohol use

    Adverse consequences of alcohol use assessed with the Short Inventory of Problems (SIP-2R) questionnaire

    Time frame: Three months after the second administration

  10. Craving

    Craving assessed with the Obsessive Compulsive Drinking Scale (OCDS)

    Time frame: Three weeks after the first administration, three weeks, two and three months after the second administration

  11. Ethyl glucuronide

    Ethyl glucuronide (EtG) in hair

    Time frame: Three months after the second administration

  12. Phosphatidylethanol

    Phosphatidylethanol (PEth) in blood

    Time frame: At each administration and three months after the second administration

  13. Perceived quality of life across multiple domains

    Quality of life assessed with the World Health Organization Quality of Life Scale (WHOQOL-bref). Domain scores are transformed to a 0-100 scale. Higher scores indicate better quality of life.

    Time frame: One and two months after the second administration

  14. Depression

    Beck Depression Inventory (BDI-II). Total score range: 0-63. Higher scores indicate more severe depressive symptoms

    Time frame: Three weeks after the first administration, one and three months after the second administration

  15. Anxiety

    Beck Anxiety Inventory (BAI). Total score range: 0-63. Higher scores indicate more severe anxiety symptoms (worse outcome)

    Time frame: Three weeks after the first administration, one and three months after the second administration

  16. Various somatic and psychological symptoms

    Various somatic and psychological symptoms assessed with the Brief Symptom Checklist (BSCL). The BSCL contains 53 items rated on a 5-point Likert scale from 0 ("not at all") to 4 ("extremely"), covering nine symptom dimensions (somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, psychoticism). The Global Severity Index (GSI) is calculated as the mean across all 53 items and ranges from 0 to 4. Higher scores indicate greater symptom burden (worse outcome).

    Time frame: Three weeks after the first administration, one and three months after the second administration

  17. World view

    World views will be assessed using the World View Questionnaire (WVQ)

    Time frame: Three weeks after the first administration, three weeks after the second administration

  18. Persisting effects

    Persisting effects of LSD assessed with the Persisting Effects Questionnaire (PEQ)

    Time frame: Three months after the second administration

  19. Mindfulness

    Mindfulness will be assessed using the Comprehensive Inventory of Mindfulness Experience (CHIME)

    Time frame: Three weeks after the first administration, three weeks after the second administration, two months after the second administration

  20. Acute effects of LSD

    Acute effects assessed with the 5 Dimensions of Altered States of Consciousness (5D-ASC). Visual analog scales range from 0 to 100. Higher scores indicate more intense effects on the respective dimension.

    Time frame: The day after the first and the day after the second administration

  21. Acute effects of LSD

    Acute effects assessed with the Mystical Experience Questionnaire (MEQ30). Each item is rated on 0 to 5, grouped into four subscales. Higher scores indicate more intense effects on the respective dimension.

    Time frame: The day after the first and the day after the second administration

  22. Acute effects of LSD

    Acute effects assessed with the General Change Mechanisms Questionnaire (GCMQ)

    Time frame: The day after the first and the day after the second administration

  23. Acute effects of LSD

    Acute effects assessed with the Phenomenological-Autobiographical-Existential Psychedelic Scale extended (PAE-PS-ext)

    Time frame: The day after the first and the day after the second administration

  24. Blinding

    Blinding will be assessed directly after session 1 with a self-developed questionnaire that includes participants' guesses of their group assignment and their degree of certainty, rated on a visual analogue scale.

    Time frame: In the evening after the first administration

  25. Expectancy

    Expectancy will be assessed with the Credibility / Expectancy Questionnaire (CEQ). Therapists' expectancy will also be assessed

    Time frame: Two weeks before the first administration

  26. Self-efficacy

    Self-efficacy will be assessed using a visual analogue scale

    Time frame: Three weeks after the first administration, three weeks after the second administration, two and three months after the second administration

  27. Drinking goals

    Drinking goals will be assessed using pre-defined response options

    Time frame: Three weeks after the first administration, three weeks after the second administration, two and three months after the second administration

  28. Safety: Adverse events

    Adverse events will be documented at each visit and each session.

    Time frame: Week 0 to week 18

  29. Qualitative Interview

    Qualitative interview regarding subjective experiences of acute drug effects, benefits, possible negative effects, as well as the subjective concept of the potential psychological mechanisms

    Time frame: Three months after the second administration

07

Study locations

2 of 2 sites recruiting
  • University Hospital of Psychiatry, University of Basel
    Basel, Switzerland
    Recruiting
    • Felix Müller, PD Dr. med. · Principal investigator
  • University Hospital of Psychiatry, University of Bern
    Bern, Switzerland
    Recruiting
    • Leila Soravia, Prof. Dr. phil. · Sub investigator
    • Tobias Bracht, Prof. Dr. med. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Oct 2028, 33 months after the start.

Of 123 non-industry phase 2 interventional studies under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 33 months is close to that.

Counting every sponsor, half of 135 studies reached it within 33 months; a quarter within 21 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2022
First posted
Jul 26, 2022
StartActual
Jan 27, 2026
Primary completionEst.
Oct 31, 2028
CompletionEst.
Apr 30, 2029
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
6 description edited
What changed in the outcomes
  • DescriptionAcute effects of LSD: how it is measured was reworded
  • DescriptionAcute effects of LSD#2: how it is measured was reworded
  • DescriptionAnxiety: how it is measured was reworded
  • DescriptionDepression: how it is measured was reworded
  • DescriptionPerceived quality of life across multiple domains: how it is measured was reworded
  • DescriptionVarious somatic and psychological symptoms: how it is measured was reworded
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Secondary outcomes 6 description edited
    What changed in the outcomes
    • DescriptionAcute effects of LSD: how it is measured was reworded
    • DescriptionAcute effects of LSD#2: how it is measured was reworded
    • DescriptionAnxiety: how it is measured was reworded
    • DescriptionDepression: how it is measured was reworded
    • DescriptionPerceived quality of life across multiple domains: how it is measured was reworded
    • DescriptionVarious somatic and psychological symptoms: how it is measured was reworded
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05474989
Lead sponsor
Felix Mueller
Collaborators
University of Bern
Responsible party
Felix Mueller (Sponsor-Investigator PD Dr. med. Felix Müller MD, University Hospital, Basel, Switzerland) — Sponsor-investigator
First posted
Jul 26, 2022
Start date
Jan 27, 2026
Primary completion
Oct 31, 2028 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Oct 7, 2026

Study contacts

Felix Müller, PD Dr. med.
Contact
felix.mueller@upk.ch
+41 (0)61 325 5111

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lysergic Acid Diethylamide

Start the discussion